{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-121461","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.721900+00:00","generated_at":"2026-05-16T13:12:46.893148+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Relmada Therapeutics amends exec employment pacts; salaries raised for CEO, COO, CFO, CAO","bullets":["CEO salary increased to $827,176 (+5% from $787,787); other terms unchanged.","COO salary increased to $524,790 (+5% from $499,800); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.","CFO salary increased to $586,940 (+5% from $558,990); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.","CAO salary increased to $576,440 (+5% from $548,990); new severance: 12 months lump sum on non-cause termination, 18 months on CIC."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-121461","json":"https://secwatch.observer/filing/0001213900-25-121461.json","markdown":"https://secwatch.observer/filing/0001213900-25-121461.md","text":"https://secwatch.observer/filing/0001213900-25-121461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121461/0001213900-25-121461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025121461/ea0269660-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:12:46.893148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}